Sotirios C. Kampranis
Tufts Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sotirios C. Kampranis.
Journal of Biological Chemistry | 2000
Sotirios C. Kampranis; Radostina Damianova; Mirna Atallah; Garabet Toby; Greta Kondi; Philip N. Tsichlis; Antonios M. Makris
The mammalian inducer of apoptosis Bax is lethal when expressed in yeast and plant cells. To identify potential inhibitors of Bax in plants we transformed yeast cells expressing Bax with a tomato cDNA library and we selected for cells surviving after the induction of Bax. This genetic screen allows for the identification of plant genes, which inhibit either directly or indirectly the lethal phenotype of Bax. Using this method a number of cDNA clones were isolated, the more potent of which encodes a protein homologous to the class θ glutathioneS-transferases. This Bax-inhibiting (BI) protein was expressed in Escherichia coli and found to possess glutathione S-transferase (GST) and weak glutathione peroxidase (GPX) activity. Expression of Bax in yeast decreases the intracellular levels of total glutathione, causes a substantial reduction of total cellular phospholipids, diminishes the mitochondrial membrane potential, and alters the intracellular redox potential. Co-expression of the BI-GST/GPX protein brought the total glutathione levels back to normal and re-established the mitochondrial membrane potential but had no effect on the phospholipid alterations. Moreover, expression of BI-GST/GPX in yeast was found to significantly enhance resistance to H2O2-induced stress. These results underline the relationship between oxidative stress and Bax-induced death in yeast cells and demonstrate that the yeast-based genetic strategy described here is a powerful tool for the isolation of novel antioxidant and antiapoptotic genes.
The Plant Cell | 2007
Sotirios C. Kampranis; Daphne Ioannidis; Alan Purvis; Walid Mahrez; Ederina Ninga; Nikolaos A. Katerelos; Samir Anssour; Jim M. Dunwell; Jörg Degenhardt; Antonios M. Makris; Peter W. Goodenough; Christopher B. Johnson
Terpene synthases are responsible for the biosynthesis of the complex chemical defense arsenal of plants and microorganisms. How do these enzymes, which all appear to share a common terpene synthase fold, specify the many different products made almost entirely from one of only three substrates? Elucidation of the structure of 1,8-cineole synthase from Salvia fruticosa (Sf-CinS1) combined with analysis of functional and phylogenetic relationships of enzymes within Salvia species identified active-site residues responsible for product specificity. Thus, Sf-CinS1 was successfully converted to a sabinene synthase with a minimum number of rationally predicted substitutions, while identification of the Asn side chain essential for water activation introduced 1,8-cineole and α-terpineol activity to Salvia pomifera sabinene synthase. A major contribution to product specificity in Sf-CinS1 appears to come from a local deformation within one of the helices forming the active site. This deformation is observed in all other mono- or sesquiterpene structures available, pointing to a conserved mechanism. Moreover, a single amino acid substitution enlarged the active-site cavity enough to accommodate the larger farnesyl pyrophosphate substrate and led to the efficient synthesis of sesquiterpenes, while alternate single substitutions of this critical amino acid yielded five additional terpene synthases.
Molecular Cell | 2011
Filippos Kottakis; Christos Polytarchou; Parthena Foltopoulou; Ioannis Sanidas; Sotirios C. Kampranis; Philip N. Tsichlis
The histone H3K27 methyltransferase EZH2 plays an important role in oncogenesis, by mechanisms that are incompletely understood. Here, we show that the JmjC domain histone H3 demethylase NDY1 synergizes with EZH2 to silence the EZH2 inhibitor miR-101. NDY1 and EZH2 repress miR-101 by binding its promoter in concert, via a process triggered by upregulation of NDY1. Whereas EZH2 binding depends on NDY1, the latter binds independently of EZH2. However, both are required to repress transcription. NDY1 and EZH2 acting in concert upregulate EZH2 and stabilize the repression of miR-101 and its outcome. NDY1 is induced by FGF-2 via CREB phosphorylation and activation, downstream of DYRK1A, and mediates the FGF-2 and EZH2 effects on cell proliferation, migration, and angiogenesis. The FGF-2-NDY1/EZH2-miR-101-EZH2 axis described here was found to be active in bladder cancer. These data delineate an oncogenic pathway that functionally links FGF-2 with EZH2 via NDY1 and miR-101.
Proceedings of the National Academy of Sciences of the United States of America | 2008
Raymond Pfau; Alexandros Tzatsos; Sotirios C. Kampranis; Oksana B. Serebrennikova; Susan E. Bear; Philip N. Tsichlis
A common integration site, cloned from MoMuLV-induced rat T cell lymphomas, was mapped immediately upstream of Not dead yet-1 (Ndy1)/KDM2B, a gene expressed primarily in testis, spleen, and thymus, that is also known as FBXL10 or JHDM1B. Ndy1 encodes a nuclear, chromatin-associated protein that harbors Jumonji C (JmjC), CXXC, PHD, proline-rich, F-box, and leucine-rich repeat domains. Ndy1 and its homolog Ndy2/KDM2A (FBXL11 or JHDM1A), which is also a target of provirus integration in retrovirus-induced lymphomas, encode proteins that were recently shown to possess Jumonji C-dependent histone H3 K36 dimethyl-demethylase or histone H3 K4 trimethyl-demethylase activities. Here, we show that mouse embryo fibroblasts engineered to express Ndy1 or Ndy2 undergo immortalization in the absence of replicative senescence via a JmjC domain-dependent process that targets the Rb and p53 pathways. Knockdown of endogenous Ndy1 or expression of JmjC domain mutants of Ndy1 promote senescence, suggesting that Ndy1 is a physiological inhibitor of senescence in dividing cells and that inhibition of senescence depends on histone H3 demethylation.
Microbial Cell Factories | 2011
Codruta Ignea; Ivana Cvetkovic; Sofia Loupassaki; Panagiotis Kefalas; Christopher B. Johnson; Sotirios C. Kampranis; Antonios M. Makris
BackgroundTerpenoids constitute a large family of natural products, attracting commercial interest for a variety of uses as flavours, fragrances, drugs and alternative fuels. Saccharomyces cerevisiae offers a versatile cell factory, as the precursors of terpenoid biosynthesis are naturally synthesized by the sterol biosynthetic pathway.ResultsS. cerevisiae wild type yeast cells, selected for their capacity to produce high sterol levels were targeted for improvement aiming to increase production. Recyclable integration cassettes were developed which enable the unlimited sequential integration of desirable genetic elements (promoters, genes, termination sequence) at any desired locus in the yeast genome. The approach was applied on the yeast sterol biosynthetic pathway genes HMG2, ERG20 and IDI1 resulting in several-fold increase in plant monoterpene and sesquiterpene production. The improved strains were robust and could sustain high terpenoid production levels for an extended period. Simultaneous plasmid-driven co-expression of IDI1 and the HMG2 (K6R) variant, in the improved strain background, maximized monoterpene production levels. Expression of two terpene synthase enzymes from the sage species Salvia fruticosa and S. pomifera (SfCinS1, SpP330) in the modified yeast cells identified a range of terpenoids which are also present in the plant essential oils. Co-expression of the putative interacting protein HSP90 with cineole synthase 1 (SfCinS1) also improved production levels, pointing to an additional means to improve production.ConclusionsUsing the developed molecular tools, new yeast strains were generated with increased capacity to produce plant terpenoids. The approach taken and the durability of the strains allow successive rounds of improvement to maximize yields.
Advances in Cancer Research | 2009
Sotirios C. Kampranis; Philip N. Tsichlis
Epigenetic modifications are heritable chromatin alterations that contribute to the temporal and spatial interpretation of the genome. The epigenetic information is conveyed through a multitude of chemical modifications, including DNA methylation, reversible modifications of histones, and ATP-dependent nucleosomal remodeling. Deregulation of the epigenetic machinery contributes to the development of several pathologies, including cancer. Chromatin modifications are multiple and interdependent and they are dynamically modulated in the course of various biological processes. Combinations of chromatin modifications give rise to a complex code that is superimposed on the genetic code embedded into the DNA sequence to regulate cell function. This review addresses the role of epigenetic modifications in cancer, focusing primarily on histone methylation marks and the enzymes catalyzing their removal.
FEBS Letters | 2004
Irina Dimitrova; Garabet G. Toby; Esmerina Tili; Randy Strich; Sotirios C. Kampranis; Antonios M. Makris
Bax‐induced lethality in yeast is accompanied by morphological changes in mitochondria, giving rise to a reduced number of swollen tubules. Although these changes are completely abolished upon coexpression of the Bax inhibitor, Bcl‐2, coexpression of Bax with Bax inhibiting‐glutathione S‐transferase (BI‐GST) leads to aggregation, but not fusion of the mitochondria. In addition, Bax affects the integrity of yeast vacuoles, resulting in the disintegration and eventual loss of the organelles, and the disruption of intracellular protein traffic. While Bcl‐2 coexpression only partially corrects this phenotype, coexpression of BI‐GST fully restores the organelles, indicating a different mode of protection exerted by Bcl‐2 and BI‐GST.
PLOS Pathogens | 2014
George Sourvinos; Antigoni Morou; Ioannis Sanidas; Ignea Codruta; Scott A. Ezell; Christina Doxaki; Sotirios C. Kampranis; Filippos Kottakis; Philip N. Tsichlis
Earlier studies had suggested that epigenetic mechanisms play an important role in the control of human cytomegalovirus (HCMV) infection. Here we show that productive HCMV infection is indeed under the control of histone H3K27 trimethylation. The histone H3K27 methyltransferase EZH2, and its regulators JARID2 and NDY1/KDM2B repress GFI1, a transcriptional repressor of the major immediate-early promoter (MIEP) of HCMV. Knocking down EZH2, NDY1/KDM2B or JARID2 relieves the repression and results in the upregulation of GFI1. During infection, the incoming HCMV rapidly downregulates the GFI1 mRNA and protein in both wild-type cells and in cells in which EZH2, NDY1/KDM2B or JARID2 were knocked down. However, since the pre-infection levels of GFI1 in the latter cells are significantly higher, the virus fails to downregulate it to levels permissive for MIEP activation and viral infection. Following the EZH2-NDY1/KDM2B-JARID2-independent downregulation of GFI1 in the early stages of infection, the virus also initiates an EZH2-NDY1/ΚDM2Β-JARID2-dependent program that represses GFI1 throughout the infection cycle. The EZH2 knockdown also delays histone H3K27 trimethylation in the immediate early region of HCMV, which is accompanied by a drop in H3K4 trimethylation that may contribute to the shEZH2-mediated repression of the major immediate early HCMV promoter. These data show that HCMV uses multiple mechanisms to allow the activation of the HCMV MIEP and to prevent cellular mechanisms from blocking the HCMV replication program.
Cancer Research | 2011
Filippos Kottakis; Christos Polytarchou; Sotirios C. Kampranis; Philip N. Tsichlis
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FLnnThe histone H3K27 methyltransferase EZH2 plays an important role in oncogenesis, by mechanisms that are incompletely understood. Here we show that NDY1/KDM2B, a JmjC domain-containing histone H3K36me2, H3K36me1 and H3K4me3 demethylase synergizes with EZH2 to silence the EZH2 inhibitor miR-101. NDY1/KDM2B and EZH2 repress miR-101 by binding its promoter in concert via a process that is activated by upregulation of NDY1/KDM2B. EZH2 does not bind the miR-101 promoter when overexpressed in the absence of NDY1/KDM2B, while NDY1/KDM2B binds the miR-101 promoter when overexpressed in the absence of EZH2, but fails to repress transcription. The concerted action of NDY1/KDM2B and EZH2, triggered by the upregulation of NDY1/KDM2B, promotes the initial upregulation of EZH2 and initiates a feedforward loop that results to the gradual upregulation of EZH2 and other miR-101 targets. NDY1/KDM2B expression was induced by FGF-2 and to a lesser degree by VEGF, via CREB phosphorylation and activation, downstream of the DYRK1A kinase. The FGF-2-NDY1-miR-101-EZH2 axis was documented in primary fibroblasts in culture, and in a set of human tumor cell lines, and it was shown to be responsible for the FGF-2 and EZH2 effects on cell proliferation, migration and angiogenesis. The axis appeared to also be active in a set of transitional cell bladder carcinomas, in which NDY1/KDM2B and FGF-2 were overexpressed in concert and their upregulation correlated with the repression of miR-101 and the upregulation of EZH2. These data delineate a novel pathway that links FGF-2 signaling with the functional and transcriptional regulation of EZH2 via NDY1/KDM2B and miR-101, and contributes to oncogenesis.nnCitation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 108. doi:10.1158/1538-7445.AM2011-108
Archive | 2007
Osama Odat; Samer Matta; Hadi Khalil; Sotirios C. Kampranis; Raymond Pfau; Philip N. Tsichlis; Antonios M. Makris